Sophie Papa, MD
Beyond hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapy could have potential in solid tumors, such as head and neck cancer, according to early results of a clinical trial presented at the 2017 AACR Annual Meeting.
during the meeting, lead study author Sophie Papa, MD, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.
OncLive: Could you please provide an overview of the study being presented at this year’s meeting?
CAR T-cell therapy has really begun to become the standard of care in hematologic cancers that express CD19, and has made a huge impact on survival for patients with resistant, heavily pretreated cancers in that setting. What we are trying to do is use a CAR T-cell approach to treat a very different type of malignancy, head and neck squamous cell carcinoma.
... to read the full story